Evidence map›Paper›PMID 36299233›Full record

ArticlePediatric transplantation2023

Prospective Evaluation of the Fungitell® (1→3) Beta-D-Glucan Assay as a Diagnostic Tool for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplantation: A Report from the Children's Oncology Group.

William R Otto, Christopher C Dvorak, Craig L K Boge, Luis Ostrosky-Zeichner, Adam J Esbenshade, Michael L Nieder, Sarah Alexander, William J Steinbach, Ha Dang, Doojduen Villaluna and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 3 countries.

William R OttoDivision of Pediatrics Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-7959-1445
Christopher C DvorakDivision of Pediatric Allergy, Immunology and Bone Marrow Transplant, University of California San Francisco, San Francisco, California, USA.
Craig L K BogeDivision of Pediatrics Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Luis Ostrosky-ZeichnerDivision of Infectious Diseases, University of Texas-Houston McGovern Medical School, Houston, Texas, USA.
Adam J EsbenshadeDivision of Pediatric Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Michael L NiederDivision of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA.
Sarah AlexanderDivision of Haematology Oncology, The Hospital for Sick Children, Toronto, Ontario, USA.
William J SteinbachDepartment of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Ha DangBiostatistics and Data Management, Johnson and Johnson Medical Devices Companies, Irvine, California, USA.
Doojduen VillalunaChildren's Oncology Group, University of Southern California, Monrovia, California, USA.
Lu ChenDivision of Biostatistics, City of Hope, Duarte, California, USA.
Micah SkeensDepartment of Hematology/Oncology, Nationwide Children's Hospital, Columbus, Ohio, USA.ORCID 0000-0001-6786-8128
Theoklis E ZaoutisDepartment of Pediatrics, National Public Health Organization, Athens, Greece.
Lillian SungDivision of Haematology Oncology, The Hospital for Sick Children, Toronto, Ontario, USA.ORCID 0000-0003-0951-3091
Brian T FisherDivision of Pediatrics Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Children's Hospital of Philadelphia · USHospital for Sick Children · CACity Of Hope National Medical Center · USJohnson & Johnson (United States) · USMoffitt Cancer Center · USNational Public Health Organization · GRNationwide Children's Hospital · USThe University of Texas Health Science Center · USUniversity of Arkansas for Medical Sciences · USUniversity of California, San Francisco · USUniversity of Southern California · USVanderbilt University Medical Center · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
T32 Institutional Pediatric ResearchT32HD043021 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI Joseph W. St. Geme · 2002 to 2026
$6.4M
Canada Research Chairs Pediatric Oncology Supportive CareMerck Investigator-Initiated GrantNCI NIH HHS U10 CA180886NCI NIH HHS U10CA 180886NCI NIH HHS U10 CA180899NCI NIH HHS U10CA 180899NCI NIH HHS UG1 CA189955NCI NIH HHS UG1CA 189955NICHD NIH HHS T32 HD043021St. Baldrick's Foundation
6 · The paper itself

Abstract

backgroundInvasive fungal disease (IFD) is a major source of morbidity and mortality for hematopoietic cell transplant (HCT) recipients. Non-invasive biomarkers, such as the beta-D-glucan assay, may improve the diagnosis of IFD. The objective was to define the utility of surveillance testing using Fungitell® beta-D-glucan (BDG) assay in children receiving antifungal prophylaxis in the immediate post-HCT period.

methodsWeekly surveillance blood testing with the Fungitell® BDG assay was performed during the early post-HCT period in the context of a randomized trial of children, adolescents, and young adults undergoing allogeneic HCT allocated to triazole or caspofungin prophylaxis. Positivity was defined at the manufacturer cutoff of 80 pg/ml. IFD was adjudicated using blinded central reviewers. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for the Fungitell® BDG assay for the outcome of proven or probable IFD.

resultsA total of 51 patients (out of 290 patients in the parent trial) contributed blood specimens. In total, 278 specimens were evaluated. Specificity was 80.8% (95% confidence interval [CI]: 75.6%-85.3%), and NPV was over 99% (95% CI: 86.8%-99.9%). However, there were no true positive results, resulting in sensitivity of 0% (95% CI: 0.0%-84.2%) and PPV of 0% (95% CI: 0.0%-6.7%).

conclusionsFungitell® BDG screening is of limited utility in diagnosing IFD in the post-HCT period, mainly due to high false-positive rates. Fungitell® BDG surveillance testing should not be performed in children during the early post-HCT period while receiving antifungal prophylaxis as the pretest probability for IFD is low.

Indexed as

beta-GlucansHematopoietic Stem Cell TransplantationInvasive Fungal InfectionsAdolescentAntifungal AgentsChildHumansRandomized Controlled Trials as TopicSensitivity and SpecificityYoung AdultAntifungal Agentsbeta-Glucansbeta-D-glucanhematopoietic cell transplantationinvasive fungal diseasesensitivityspecificity

Identifiers

PMID36299233
PMCPMC9885553
OpenAlexW4307580705

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.